In short
Lixisenatide is being studied in clinical trials for adults with type 2 diabetes. These trials look at how it compares with other diabetes treatments and measure results such as blood sugar control and overall treatment effect. The main focus is on adults with type 2 diabetes in a Phase 3 study.
Key points
- Lixisenatide is included in a Phase 3 clinical trial for adults with type 2 diabetes. The study is an interventional trial, which means treatments are being compared directly. The main outcome is change in HbA1c, a blood test that shows average blood sugar over time. The trial follows participants to Week 104, or about 2 years. The study is authorised and includes 781 participants. It is part of research focused on blood sugar control in type 2 diabetes.
Trial overview
The clinical trial data show one study that includes Lixisenatide as part of treatment for adults with type 2 diabetes. The study is named SURPASS-EARLY and is an interventional trial, which means researchers are comparing treatment plans rather than just observing people.
Study design and phase
This trial is a Phase 3 study. Phase 3 trials are later-stage studies that test treatments in larger groups and compare how well they work. The trial is authorised and includes 781 participants.
Who can participate
The trial is designed for adult participants with type 2 diabetes. The source data do not list more detailed entry rules, so the main target group is adults living with this condition.
What is being measured
The main outcome is the change from baseline in Hemoglobin A1c (HbA1c). HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see how well treatment controls diabetes. The brief summary says the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104. Non-inferior means the treatment is not worse than the comparison by more than a set amount.
Trial details
The trial compares tirzepatide with intensified conventional care, which means stronger standard diabetes treatment. The intervention list also includes several other diabetes medicines and treatment options, such as semaglutide, dulaglutide, exenatide, liraglutide, sitagliptin, and Lixisenatide. The data provided do not explain the exact role of each listed treatment arm, but they show that Lixisenatide is one of the treatments included in this comparison study.
The study follows participants for 104 weeks, which is about 2 years. This long follow-up helps researchers see how treatment effects change over time.
In simple terms, this trial is trying to learn whether the study treatment plan can control blood sugar as well as, or better than, standard care in adults with type 2 diabetes.